H. Lundbeck A/S

History

Year	Detail
1915	On 14 August 1915, Hans Lundbeck founded a company in Copenhagen, Denmark, which dealt with everything from machinery to biscuits.
1922	Schizophrenic patients started to be treated with Somnifen-Dauerschlaf therapy. Patients were given large doses of Somnifen (a barbiturate drug), making them sleep all day long for two-three weeks at a time.
1929	Hans Berger demonstrated the first human Electroencephalograph (EEG), an instrument for measuring and recording the brain's electrical activity. Berger’s invention is now used routinely as a diagnostic test in neurology and psychiatry and as a standard tool in brain research.
1937	The company developed the first original Lundbeck product, Epicutan, for wound healing in collaboration with the Carlsberg Foundation's biological institute.
1954	The company established the Lundbeck Foundation to expand Lundbeck’s business and provide financial support for primarily scientific objectives and the fight against diseases.
1959	The company launched Truxal, one of the first antipsychotics in the world, which, through the 1960s and 1970s, became the company’s most-sold product.
1972	The company expanded its international presence by opening new offices in New York and Paris. Further, it established Lundbeck Ltd. in Luton, U.K., to grow its operations and strengthen its footprints in the healthcare market.
2003	Lundbeck acquired Synaptic, a US-based research company, establishing a research unit as a bridgehead in the U.S. and expanding its portfolio in G-protein-coupled receptors.
2009	Lundbeck acquired Ovation Pharmaceuticals Inc., which specialized in rare diseases, particularly neurology and hematology, for approximately $900 million. This acquisition established Lundbeck's commercial platform in the U.S. and expanded its portfolio in central nervous system treatments.
2009	The company acquired Elaiapharm, a pharmaceutical manufacturing company based in Sophia Antipolis, France. This acquisition provided the company with manufacturing and distribution within the European Union, enhancing its supply chain efficiency.
2011	Lundbeck expanded its global reach by establishing a new research center in China. The center was designed to strengthen the company's presence in Asia and focus on developing treatments for brain diseases.
2011	The company partnered with Otsuka Pharmaceutical Co. Ltd, a renowned Japanese pharmaceutical company, to co-develop and commercialize innovative medicines targeting psychiatric disorders.
2014	Lundbeck expanded its market presence in the U.S. by acquiring Chelsea Therapeutics and the compound Northera, which is used to treat symptomatic neurogenic orthostatic hypotension (NOH).
2019	Lundbeck acquired Abide Therapeutics in California, adding a unique discovery platform for potent and selective serine hydrolase inhibitors. These inhibitors have the potential to address multiple indications in psychiatry and neurology. After closing, Abide Therapeutics was renamed La Jolla Research Center and serves as Lundbeck’s drug discovery hub in the U.S.
2019	The company acquired Alder Biopharmaceuticals in Washington and is committed to transforming migraine treatment and prevention. Expansion of the portfolio addressed the unmet need for migraine prevention.
2020	The company launched Vyepti in the U.S. to prevent migraines in adults. This marked a significant addition to the company's CNS portfolio.
2021	The company partnered with the Department of Neurosurgery at Rigshospitalet to study fluids surrounding the brain to learn which compounds enter the brain and how they are distributed.
2021	The company collaborated with Rgenta Therapeutics, a US-based company, to discover small molecules targeting RNA regulation and the splicing of disease-causing genes.
2023	Neuro3 Therapeutics (Neuro3), a biotechnology company focused on discovering and developing innovative medicines for treating central nervous system (CNS) diseases, acquired exclusive worldwide rights to develop and commercialize clinical-stage KCNQ2 activators from Lundbeck.
2024	Lundbeck partnered with Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, to utilize its AI-powered drug discovery platform to accelerate research and therapeutic innovation for neurological disease.
2024	The company acquired Longboard Pharmaceuticals Inc. for approximately $2.5 billion net of cash to gain access to bexicaserin, a novel 5-HT2C agonist in development for the treatment of seizures associated with DEEs, including Dravet syndrome, Lennox-Gastaut syndrome, and other rare epilepsies.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.